07.28.26 -- Contamination Control By Design: A Competitive Advantage For CDMOs

Learn how disciplined containment, proactive risk management, and collaboration accelerate complex oncology programs under tight timelines while protecting quality, safety, and global launch readiness.

A science‑driven roadmap, from QTPP to QbD and phase‑appropriate strategies, helps ensure biologics stability, manufacturability, and a smooth path to successful commercialization

Rapid analytical testing turnaround is essential to maintaining development timelines, meeting clinical milestones, and in commercial manufacturing, providing reliable drug supply to patients.

An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

Regulatory and quality compliance are built into every stage of biologics development, helping ensure consistent manufacturing, faster approvals, and dependable global market access.

To maximize the results of viral titer and full capsids, it's necessary to undertake systematic process development and optimization of AAV production. The choice of cell culture medium is foundational.

Uncover how process design, effective technology transfer, and robust process characterization can accelerate validation readiness and help move biologics from development to success.

High-volume biologics and home-based care requires specialized expertise. Collaborative partnerships bridge the gap between complex drug-delivery requirements and successful commercial market entry.

CEO Kenneth Bilenberg discusses building a CDMO's success on trust, reliability, and true partnership. The path focuses on agility to support biologics growth and the reshoring of U.S. manufacturing.

Asher Biotherapeutics was seeking a CDMO that could handle Phase 2 through to commercial production, as well as taking early-stage projects in its pipeline all the way through their lifecycle.